Hillsborough, CA, United States of America

David V Goeddel

This inventor holds 92 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents, primarily in Apoptosis Regulators (CPC class 4351723). Top assignees: Genentech, Inc., Tularik Limited, Amgen Inc.. Active years: 1982-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David V Goeddel. Retrieved from https://idiyas.com/inventor/david-v-goeddel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 92

% Patents Active = 91.3

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 2.3

ph-index = 28

Forward Citations = 1,850(Granted Patents)

Forward Citations (Not Self Cited) = 1,779(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Hillsburough, CA (US) (1993)
Forestview, CA (US) (1994)
South San Francisco, CA (US) (1996)
Hillborough, CA (US) (1998)
Burlingame, CA (US) (1982 - 2003)
Hillsborough, CA (US) (1988 - 2010)

Company Filing History:

Hoffmann-La Roche Inc.

Washington University

patents

8. 4 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1982-2010

Loading Chart...

Areas of Expertise:

Tumor Necrosis Factor

Apoptosis Inhibitors

Human Tissue Plasminogen Activators

TRAF Inhibitors

Recombinant Interferons

Protein Tyrosine Kinase

SODD Genes

NIK-Knockout Mice

Microbial Production

Human Growth Hormone

Death Domains

DHFR Protein

92 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7754858 - Antibodies to tumor necrosis factor receptor associated factor polypeptides (2010-07-13),

2. 7528244 - Regulators of apoptosis (2009-05-05),

3. 7244836 - Tumor necrosis factor receptor-associated factors (2007-07-17),

4. H0002181 - Human tPA production using vectors coding for DHFR protein (2007-02-05),

5. 7029871 - RIP: a human protein involved in tumor necrosis factor signal transduction (2006-04-18),

6. 6964765 - Inhibitors of apoptosis (2005-11-15),

7. 6855815 - Inhibitors of apoptosis (2005-02-15),

8. 6838550 - Suppressors of death domains (2005-01-04),

9. 6822138 - NIK-knockout mice (2004-11-23),

10. 6821736 - Inhibitors of apoptosis (2004-11-23),

11. 6673343 - SAL-S1 receptor protein tyrosine kinase agonist antibodies (2004-01-06),

12. 6610830 - Microbial production of mature human leukocyte interferons (2003-08-26),

13. 6500922 - Tumor necrosis factor receptor-associated factors (2002-12-31),

14. 6482613 - Microbial production of mature human leukocyte interferons (2002-11-19),

15. 6437113 - Suppressors of death domains (2002-08-20),

Title: Pioneering the Biopharmaceutical Industry: The Innovations of David V Goeddel

Introduction: David V Goeddel, a renowned inventor in the field of biopharmaceuticals, hailing from Hillsborough, CA, has made significant contributions with an impressive portfolio of 92 patents.

Latest Patents:

1. Antibodies to tumor necrosis factor receptor associated factor polypeptides: Goeddel's groundbreaking invention introduces antibodies to novel tumor necrosis factor receptor associated factors (TRAF), which play a crucial role in mediating tumor necrosis factor (TNF) biological activities.

2. Regulators of apoptosis: His innovation focuses on apoptosis regulating proteins, specifically Casper proteins, offering methods and compositions for their production from transformed host cells or purification from human cells. This invention opens new avenues in diagnosis, therapy, and the biopharmaceutical industry.

Career Highlights: Goeddel's expertise has been honed through his tenure at esteemed companies such as Genentech, Inc. and Tularik Limited, where he has made significant strides in the biopharmaceutical sector.

Collaborations: Throughout his career, Goeddel has collaborated with notable peers such as William J Kohr and Diane Pennica, collectively driving innovation and excellence in the field of biopharmaceuticals.

Conclusion: David V Goeddel's prolific career and groundbreaking inventions stand as a testament to his enduring legacy in the realm of biopharmaceutical innovations, shaping the future of medicine and healthcare with his unparalleled contributions.

Profile summary based on public USPTO records.